This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbott Awards Two Scholarships To Inspirational Students Living With Cystic Fibrosis

ABBOTT PARK, Ill., Oct. 12, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the winners of the CFCareForward Thriving Undergraduate and Graduate Scholarship award.  Mark Moening, a Virginia Beach, Va. resident, and Wesley McSparin, a native of Paducah, Ky., were unveiled as the 2012 Thriving Undergraduate and Graduate Scholarship recipients, respectively.  In celebration of the 20 th anniversary of the program, the total award is $20,000.

Earlier this year, 40 undergraduate and graduate students living with cystic fibrosis (CF), including the Thriving Scholarship winners, were awarded $2,500 scholarships for use during the 2012-2013 school year based on their impressive academic merits, community involvement, extracurricular activities and creativity.  All 40 students then engaged in a month-long campaign for public votes which helped to determine the two recipients of the Thriving Scholarship awards.  The creative works of all scholarship students were inducted into the 2012 CFCareForward Scholarship recipient gallery and can be viewed online at www.

"Abbott is proud to recognize the enduring spirit and hard work of this talented group of young adults living with CF and to support their higher educational endeavors with scholarship funding this year," said Jim Hynd, divisional vice president, Cardiovascular Care, Metabolics and GI Care.  "The positive reception we have received from the CF community over the past two decades continues to underscore the importance of upholding the tradition of this program."

Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive systems of approximately 30,000 children and adults in the United States.  More than 70 percent of people with CF are diagnosed by age two.  

Due to advances in medical treatments, more young adults with CF are living longer, healthier lives than ever before, and increasingly are pursuing higher education.  Today, more than 45 percent of people living with CF are aged 18 or older.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs